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Abstract: Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated serious 
complication of heparin therapy characterized by thrombocytopenia and high risk for venous 
and arterial thrombosis: HIT and thrombosis syndrome (HITTS). Argatroban, a direct thrombin 
  inhibitor, is indicated as the anticoagulant for the treatment and prophylaxis of thrombosis in 
patients with HIT and in patients undergoing percutaneous coronary intervention (PCI) who have 
HIT. The aim of this review is to examine the pharmacological characteristics and the clinical 
efficacy and safety of this drug in adults with HIT, including those undergoing PCI. Briefly, 
2 prospective multicenter, nonrandomized, open-label studies evaluated the efficacy and safety 
of argatroban as an anticoagulant in patients with HIT or HITTS. Both studies showed that the 
incidence of the primary efficacy end point, a composite of all-cause death, all-cause amputation, 
or new thrombosis, was reduced in argatroban-treated patients vs control subjects with HIT or 
HITTS. In both studies, bleeding rates were similar between the groups. Argatroban was evaluated 
as the anticoagulant therapy in 3 prospective, multicenter, open-label studies in HIT patients who 
underwent PCI. The studies were similar in design with respect to patient inclusion and exclusion 
criteria, the argatroban dosing regimen, and primary efficacy outcomes. The investigators per-
formed a pooled analysis of these studies, which showed that most ($95%) patients achieved a 
satisfactory outcome from the procedure and adequate   anticoagulation (coprimary end points).
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Introduction
Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated serious 
complication of heparin therapy characterized by thrombocytopenia and high risk 
for venous and arterial thrombosis: HIT and thrombosis syndrome (HITTS).1 Two 
distinct types of HIT can occur: nonimmune and immune-mediated HIT. Nonimmune 
HIT, which occurs more frequently, is characterized by a mild decrease in the platelet 
count and is not harmful. The second type, immune-mediated HIT, occurs much less 
frequently but is dangerous. Immune-mediated HIT causes much lower platelet counts. 
Paradoxically, despite a very low platelet count, patients who suffer from HIT are at 
risk for major clotting problems.2
Immune-mediated HIT usually occurs from 5 to 14 days after first beginning 
  heparin therapy. However, there are exceptions, with HIT infrequently   developing 
either early (after a recent previous exposure to heparin) or late after heparin 
  exposure.2 Heparin has high affinity for platelet factor 4 (PF4), a positively charged 
protein found in platelet  α-granules and on some cell surfaces including platelets 
and endothelial cells. When heparins and PF4 bind, PF4 undergoes a conformational Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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change,   exposing neoepitopes that act as immunogens 
and lead to the generation of   heparin–PF4 antibodies.3 
The condition of HIT is caused by such antibodies, most 
frequently IgG, binding to the heparin–PF4 complex. The 
heparin–PF4   antibodies (sometimes called “HIT antibod-
ies”) in the resultant multimolecular immune complex 
activate platelets via their Fc receptors, causing the release 
of prothrombotic platelet-derived microparticles, platelet 
consumption, and thrombocytopenia.3 The microparticles 
in turn promote excessive thrombin generation, frequently 
resulting in thrombosis. The antibody–antigen complexes 
also interact with monocytes, leading to tissue factor pro-
duction, and thus antibody-mediated endothelial injury may 
occur. Both of these latter processes may contribute further 
to thrombosis.3 The pathogenesis of HIT is summarized in 
Figure 1.
For patients who are receiving heparin or have received 
heparin within the previous 2 weeks, the American   College 
of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (Eighth Edition) recommend investigating for a 
diagnosis of HIT if the platelet count falls by .50% and/or 
a thrombotic event occurs between days 5 and 14 (inclusive) 
following the initiation of heparin, even if the patient was 
no longer receiving heparin therapy when the thrombosis 
or thrombocytopenia occurred.4 Thrombocytopenia is 
common in hospitalized patients receiving unfractionated 
heparin (UFH), yet only a minority have HIT. A clinical 
scoring system may be useful for identifying those with HIT. 
Table 1 summarizes a clinical scoring system (4 T’s) for 
estimating the pretest probability of HIT based on its char-
acteristic features (thrombocytopenia, timing, thrombosis) 
and the absence of other explanation(s).1
Two types of assays for HIT, washed platelet   activation 
assays and commercial PF4 enzyme immunoassays, are 
  sensitive in detecting clinically relevant HIT antibodies; 
thus, a negative test generally rules out HIT. However, 
because weak (nonpathogenic) antibodies can also be 
detected (especially by enzyme immunoassays), a posi-
tive test does not necessarily confirm HIT, especially if 
the test is only weakly positive and suggests an alternative 
  explanation.1 It is important to interpret the test in the appro-
priate clinical context.
Argatroban, a direct thrombin inhibitor, is indicated as the 
anticoagulant for the treatment and prophylaxis of thrombosis 
in patients with HIT. The aim of this review is to examine 
the pharmacological characteristics and the clinical efficacy 
and safety of this drug in adults with HIT, including those 
undergoing percutaneous coronary intervention (PCI).
Argatroban: pharmacological 
characteristics, dosage,  
and monitoring therapy
Argatroban is a synthetic direct thrombin inhibitor derived 
from L-arginine that reversibly binds to the thrombin active 
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Figure 1 Pathogenesis of HiT: Heparin binds with PF4, which exposes neoepitopes 
on PF4 and leads to antibody production (1). Heparin–PF4–igG immune complexes 
form (2), and igG in the multimolecular complex triggers platelet activation via 
binding  to  Fc  receptors  (3).  Activated  platelet  releases  additional  PF4  (4a)  and 
prothrombotic platelet microparticles (4b), which enhance coagulation reactions. 
Thrombotic risk is further promoted by the binding of PF4 to heparin-like molecules 
(heparin sulfate molecules) on eC, contributing to antibody-mediated endothelial 
injury (5).
Reprinted with permission from Jang iK, Hursting MJ. when heparins promote 
thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111: 
2671–2683.3 Copyright © 2005 wolters Kluwer Health.
Abbreviations: HiT, heparin-induced thrombocytopenia; PF4, platelet factor 4; 
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site. Argatroban exerts its anticoagulant effects by inhibiting 
thrombin-catalyzed or thrombin-induced reactions, includ-
ing fibrin formation; activation of coagulation factors V , VIII, 
and XIII; activation of protein C; and platelet aggregation. 
Argatroban is capable of inhibiting the action of both free 
and clot-associated thrombin.5 When argatroban is adminis-
tered by continuous infusion, immediately upon the initiation 
of infusion, anticoagulant effects are produced as its plasma 
concentrations begin to rise. Steady-state levels of both 
drug and anticoagulant effects are typically attained within 
1–3 hours and are maintained until the infusion is discontin-
ued or the dosage adjusted. The argatroban dose dependently 
increases the activated partial thromboplastin time (aPTT), 
the activated clotting time (ACT), the prothrombin time, the 
international normalized ratio (INR), and the thrombin time 
in healthy volunteers and cardiac patients.5
In adult patients with HIT or HITTS and without hepatic 
impairment, after discontinuation of heparin therapy and 
after determining baseline aPTT, the recommended initial 
dosage of argatroban is 2 µg/kg/min administered as a con-
tinuous infusion. The aPTT should be checked 2 hours after 
the initiation of therapy and after every dosage adjustment 
(not to exceed 10 µg/kg/min), until the steady-state aPTT 
is 1.5–3.0 times the initial baseline value (not to exceed 
100 seconds).5
In adult patients with HIT or HITTS undergoing PCI, 
after determining the baseline ACT, argatroban infusion 
should be started at 25 µg/kg/min and an intravenous (IV) 
bolus of 350 µg/kg administered over 3–5 minutes. The ACT 
should be checked 5–10 minutes after the bolus is completed. 
If the ACT is less than 300 seconds, an additional IV bolus 
dose of 150 µg/kg should be administered, the   infusion 
dose increased to 30 µg/kg/min, and the ACT checked 
5–10 minutes later. If the ACT is greater than 450 seconds, 
the infusion rate should be decreased to 15 µg/kg/min, and 
the ACT checked 5–10 minutes later. Once a therapeutic 
ACT (between 300 and 450 seconds) has been achieved, 
this infusion dose should be continued for the duration of the 
procedure. In case of dissection, impending abrupt closure, 
thrombus formation during the procedure, or inability to 
achieve or maintain an ACT over 300 seconds, additional 
bolus doses of 150 µg/kg may be administered and the infu-
sion dose increased to 40 µg/kg/min. The ACT should be 
checked after each additional bolus or change in the rate 
of infusion. Additional ACTs should be drawn about every 
20–30 minutes during a prolonged procedure and at the end 
of PCI procedure. If a patient requires anticoagulation after 
the procedure, argatroban may be continued, but at lower 
infusion dosages (those recommended for patients with HIT 
or HITTS).5
No initial dosage adjustment is required in patients 
with renal impairment.5 In adult patients with hepatic 
impairment and HIT or HITTS, the initial infusion dosage 
should be reduced to 0.5 µg/kg/min and aPTT should be 
monitored closely; similarly, in adult patients with HIT or 
HITTS and hepatic impairment who are undergoing PCI, 
argatroban dosages should be titrated carefully to achieve 
therapeutic ACTs.5 Use of high doses of argatroban in PCI 
patients with clinically significant hepatic disease or alanine 
  aminotransferase/aspartate aminotransferase levels $ 3 times 
the upper limit of normal should be avoided.5
Although the approved initial dosage of argatroban 
(as recommended by the manufacturer) for adults with 
HIT or HITTS is 2 µg/kg/min in patients with normal 
hepatic   function and 0.5 µg/kg/min in patients with 
hepatic   dysfunction, there is evidence that a reduced initial 
dose may also be prudent for patients with heart failure, 
  multiple organ-system failure, severe anasarca, or after 
Table 1 estimating the pretest probability of HiT: the “4 T’s”
Points (0, 1, or 2 for each of 4 categories: maximum possible score = 8)
2 1 0
Thrombocytopenia .50% platelet fall to nadir $ 20 30%–50% platelet fall or nadir 10–19 ,30% platelet fall or 
nadir , 10
Timinga of onset of platelet fall 
(or other sequelae of HiT)
5–10 d or #1 d with recent heparin  
(past 30 d)
.10 d or timing unclear or ,1 d with  
recent heparin (past 30–100 d)
,4 d (no recent heparin)
Thrombosis or other sequaele Proven new thrombosis; skin necrosis; or  
acute systemic reaction after intravenous  
UFH bolus
Progressive or recurrent thrombosis; 
erythematous skin lesions; suspected 
thrombosis (not proven)
None
Other causes of platelet fall None evident Possible Definite
aFirst day of immunizing heparin exposure considered day 0.  
Reprinted with permission from warkentin Te. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004;110:e454–e458.1 Copyright © 2004 
wolters Kluwer Health.
Notes: Pretest probability score: 6–8 indicates high; 4–5, intermediate; and 0–3, low.
Abbreviations: HiT, heparin-induced thrombocytopenia; UFH, unfractionated heparin.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
816
Babuin and Pengo
cardiac surgery (ie, conditions associated with hepatic 
congestion/dysfunction, which may potentially decrease 
argatroban clearance).6–12 Based on these observations of 
mean doses used in recent reports of argatroban-treated 
patients13–16 and in a multicenter registry,17,18 the   American 
College of Chest Physicians Evidence-Based Clinical 
Practice Guidelines (Eighth Edition) suggests lower initial 
dosages of argatroban (0.5–1.2 µg/kg/min) in the aforemen-
tioned clinical settings, as well as for patients with hepatic 
impairment. Moreover, no initial dosage adjustment is sug-
gested in patients with renal impairment, however, in the 
absence of the aforementioned conditions4.
Argatroban is contraindicated in patients with overt 
major bleeding. Extreme caution is advised during the use of 
  argatroban in conditions or circumstances that increase the 
risk of hemorrhage, such as severe hypertension; immediately 
following lumbar puncture; spinal anesthesia; major sur-
gery, especially involving the brain, spinal cord, or eye; and 
hematologic conditions associated with increased bleeding 
tendencies such as congenital or acquired bleeding disorders 
and gastrointestinal lesions such as ulcerations.5
There is no specific antidote to argatroban overdose; 
thus, if life-threatening bleeding occurs or excessive plasma 
concentrations of argatroban are suspected, therapy should be 
discontinued immediately, aPTT should be performed, and 
symptomatic therapy should be provided to the patient.5
When switching to oral anticoagulant therapy after 
argatroban treatment, the potential for combined effects of 
argatroban and warfarin on INR measurements should be 
taken into consideration. It is suggested that argatroban and 
warfarin therapy should be overlapped to avoid prothrom-
botic effects and to ensure continuous anticoagulation when 
initiating warfarin. Warfarin therapy should be initiated at 
the expected daily dose; a loading dose of warfarin should 
not be used. The INR values should be measured daily while 
coadministering these agents. Generally, argatroban can 
be discontinued when the INR is .4 following treatment 
with argatroban (up to 2 µg/kg/min) and warfarin. The INR 
should be measured again 4–6 hours after discontinuation 
of argatroban, and if the repeat INR is below the therapeutic 
range, argatroban infusion may be resumed. This procedure 
should be repeated daily until the desired therapeutic INR is 
achieved with warfarin alone.5
Argatroban in adults with HIT
Two prospective multicenter, nonrandomized, open-label 
studies (ARG-911 and ARG-915 studies) evaluated the 
  efficacy and safety of argatroban as an anticoagulant in 
patients with HIT or HITTS. When these studies were 
  initiated, no approved alternative agent was available for use 
as an active comparator; therefore, historical control subjects 
were studied for comparison. Patients were assigned at enroll-
ment to either the HIT study arm (for those with isolated HIT) 
or the HITTS study arm (for those with HIT complicated by 
thrombosis that occurred after heparin initiation).19,20
Eligible patients had thrombocytopenia, defined as a 
  platelet count ,100 × 109/L, or a 50% reduction in count after 
heparin therapy with no explanation besides HIT. Patients 
who had a documented history of positive HIT   antibody 
(ie, latent disease) and who required   anticoagulation were 
eligible for the HIT arm, in the absence of   thrombocytopenia 
or heparin challenge.19,20
All patients with an unexplained aPTT value . 2 times 
the control at baseline; a documented coagulation disorder 
or bleeding diathesis unrelated to HITTS; a lumbar puncture 
within the past 7 days; or a history of previous aneurysm, 
hemorrhagic stroke, or recent (within 6 months) thrombotic 
stroke unrelated to HITTS were excluded.19,20
Historical control cases were identified by means of 
prospectively agreed on, documented approaches, which 
included a review of the laboratory logs of patients who were 
tested for HIT or were thrombocytopenic. Control subjects 
were treated according to the local standard of practice at the 
time of HIT diagnosis, with typical treatments being heparin 
discontinuation and/or oral anticoagulation.19,20 The historical 
controls used in the ARG-915 study were drawn from the 
same historical controls used in the ARG-911 study. Study 
ARG-915 included an initial phase in which 264 patients 
were enrolled and an extension phase in which the remaining 
patients were enrolled.
The ARG-911 study showed that the incidence of the 
primary efficacy end point, a composite of all-cause death, 
all-cause amputation, or new thrombosis, was reduced 
  significantly in argatroban-treated patients vs control 
  subjects with HIT (25.6% vs 38.8%, P = 0.014). In HITTS, 
the   composite incidence in argatroban-treated patients was 
43.8% vs 56.5% in control subjects (P = 0.13). Significant 
differences between groups were noted by time-to-event 
analysis of the composite end point–favored argatroban 
treatment in HIT (P = 0.01, Figure 2) and HITTS (P = 0.014, 
Figure 3). Argatroban therapy, relative to control subjects, 
also significantly reduced new thrombosis and death caused 
by thrombosis (P , 0.05).19
The ARG-915 study showed that in the HIT arm, 
the composite end point was significantly reduced in 
argatroban-treated patients vs control subjects with HIT Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(28.0% vs 38.8%, P = 0.04). In the HITTS arm, the composite 
end point occurred in 41.5% of argatroban-treated patients 
vs 56.5% of control subjects (P = 0.07). According to the 
time-to-event analysis of the composite end point, argatroban 
therapy was significantly better than historical control therapy 
in HIT (P = 0.02, Figure 2) and HITTS (P = 0.008, Figure 
3) cases. Argatroban therapy also significantly reduced 
new thrombosis in HIT and HITTS cases and death due to 
thrombosis in HITTS.20 In both studies, bleeding rates were 
similar among groups.19,20
Argatroban in adults with HIT 
undergoing PCI
In 3 prospective, multicenter, open-label studies (ARG-
216, ARG-310, and ARG-311 studies) in which HIT 
patients underwent PCI, argatroban was evaluated as the 
  anticoagulant therapy. The studies – a dose confirmation 
study and 2 efficacy and safety studies – were similar in 
design with respect to patient inclusion and exclusion criteria, 
the argatroban dosing regimen, primary efficacy outcomes, 
and recorded outcomes. The investigators performed a pooled 
analysis of these studies and reported the outcomes of 91 HIT 
patients who underwent 112 separate coronary interventions 
on a total of 177 treated lesions (149 in the initial group and 
28 in the repeat group).21
Eligible patients were males or nonpregnant females 
.18 years old with a documented history of HIT as   evidenced 
by a previous or current positive HIT antibody test, or a 
previous or current clinical diagnosis of HIT. The HIT 
condition was defined as a platelet count <100 × 109/L or a 
50% reduction in platelet count after the initiation of heparin 
with no other apparent cause than HIT. Eligible patients also 
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Figure 2 Time to first event for composite end point: HIT study arm.
Reprinted with permission from Lewis Be, wallis De, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 
2001;103:1838–1843.19 Copyright © 2001 wolters Kluwer Health.
Abbreviation: HiT, heparin-induced thrombocytopenia.
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Figure 3 Time to first event for composite end point: HITTS study arm.
Reprinted with permission from Lewis Be, wallis De, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 
2001;103:1838–1843.19 Copyright © 2001 wolters Kluwer Health.
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had coronary artery disease requiring elective, urgent, 
or emergent PCI. Use of any approved device including 
balloon angioplasty, atherectomy, or stent implantation 
was allowed. Patients were excluded if they had clinically 
relevant hepatic dysfunction; uncontrolled hypertension; 
documented bleeding diathesis; uncontrolled peptic ulcer 
disease, or gastrointestinal bleeding within 6 weeks; 
hypersensitivity to aspirin or argatroban; previous history 
of hemorrhagic stroke; suffered thrombotic stroke within 
the past 7 days; were pregnant or lactating; or had received 
heparin within 6 hours of dosing, a thrombolytic agent 
within 24 hours, or warfarin within 72 hours. Concomi-
tant use of a glycoprotein IIb/IIIa receptor antagonist was 
disallowed.21
Patients received oral aspirin (325 mg) 2–24 hours before 
PCI. After sheath placement, a 350 µg/kg bolus of argatroban 
was administered over 3–5 minutes, and a continuous IV 
infusion was initiated at 25 µg/kg/min (30 µg/kg/min in ARG-
216). The ACT was measured 5–10 minutes after comple-
tion of the bolus. The infusion dose was adjusted between 
15–40 µg/kg/min (20–40 µg/kg/min in ARG-216), and up 
to 3 additional bolus doses of 150 µg/kg were allowed to 
achieve and maintain ACTs of 300–450 seconds during PCI. 
The ACT was measured after each bolus dose, at the end of 
PCI, and as clinically indicated during and after PCI. At the 
investigator’s discretion, argatroban anticoagulation was con-
tinued postprocedurally at a reduced dose (,10 µg/kg/min), 
adjusted to achieve an aPTT 1.5–3.0 times the   preprocedural 
value. The mean dosages of argatroban during the infusion 
were 23 and 22 µg/kg/min in the initial and the repeat PCI 
groups, which were administered for a mean of 1.2 hours; 
after PCI, 44 patients received reduced argatroban dosages 
(,10 µg/kg/min) for 2.1 days.21
Patients were followed during argatroban infusion 
and for 24 hours after its cessation. The primary efficacy 
  outcomes were subjective assessments by the investigator 
of the attainment of a satisfactory outcome of the   procedure 
and of adequate anticoagulation during the procedure. 
Secondary objective assessments of efficacy included the 
lack of acute major complications (ie, the absence of death, 
emergent coronary artery bypass graft surgery, or Q-wave 
myocardial infarction), attainment of angiographic success 
(ie, a final stenosis of ,50% in $1 lesion attempted), and 
attainment of clinical success (ie, angiographic success 
plus the lack of acute major complications). The incidence 
of death, any   myocardial infarction, or revascularization 
(emergency   coronary artery bypass graft surgery or repeat 
PCI) at 24 hours was determined for each group.21
The primary end point of a satisfactory outcome of the 
procedure was attained in 94.5% of the initial group and 
100% of the repeat group. An unsatisfactory outcome of the 
procedure was reported in 5 patients in the initial group.21
The other coprimary efficacy end point was the achieve-
ment of adequate anticoagulation during the procedure. 
In the initial and repeat groups, respectively, 97.8% and 
100% of patients achieved adequate anticoagulation. 
Inadequate anticoagulation was noted in 2 patients in the 
initial group.
Of these 2 patients, 1 never attained an ACT in the target 
range of 300–450 seconds (however, PCI was performed and 
clinical success was achieved in 1 patient, as the   investigators 
considered the anticoagulation to be sufficient), whereas the 
other patient required emergent revascularization despite 
achieving clotting times within the target range.21
No major acute complications (ie, death, emergent 
coronary artery bypass graft surgery, or Q-wave myocardial 
infarction) occurred in 97.8% and 100%, respectively, of 
patients in the initial and repeat groups. In the initial group, 
no patient died, repeat PCI occurred in 3 (3%) patients, 
emergent coronary artery bypass graft surgery occurred in 
2 (2%) patients (one of whom first underwent repeat PCI), 
and myocardial infarction (each non-Q-wave) occurred in 
4 (4%) patients. In the repeat group, there was no death, 
periprocedural revascularization, or myocardial infarction. 
Overall, the composite of these events occurred in 7 (7.7%) 
patients in the initial group and in none of the patients (0%) 
in the repeat group.21
Conclusion
Argatroban improved clinical outcomes and was generally 
well tolerated in adults with HIT. In 2 pivotal, open-label, 
historically controlled studies conducted on adults with 
HIT, the incidence of the primary composite end point 
was significantly lower in argatroban recipients than in 
  historical controls, and more argatroban recipients than 
historical controls stayed event-free during the study. Based 
on this evidence, for patients with strongly suspected (or 
confirmed) HIT, whether or not complicated by thrombosis, 
the American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (Eighth Edition) recommend 
the use of argatroban (grade of recommendation 1C), as 
well as other nonheparin anticoagulants (danaparoid [grade 
of recommendation 1B], lepirudin [grade of recommenda-
tion 1C], fondaparinux [grade of recommendation 2C], or 
bivalirudin [grade of recommendation 2C]), over the further 
use of UFH or low-molecular-weight heparin therapy or Vascular Health and Risk Management
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initiation/continuation of vitamin K antagonists (grade of 
recommendation 1B).4
Moreover, argatroban was found to be an effective 
  anticoagulant in patients with HIT undergoing PCI from the 
pooled data from 3 small, uncontrolled trials, which showed 
that most patients achieved a satisfactory outcome of the PCI 
procedure and adequate anticoagulation.21 Accordingly, these 
data support argatroban as an alternative anticoagulant for 
HIT patients during PCI.
Finally, although the approved initial dosage of   argatroban 
(as recommended by the manufacturer) for adults with HIT or 
HITTS is 2 µg/kg/min in patients with normal hepatic func-
tion and 0.5 µg/kg/min in patients with hepatic   dysfunction, 
there is evidence that a reduced initial dose may also be 
prudent for patients with heart failure, multiple organ-system 
failure, severe anasarca, or after cardiac surgery (ie, condi-
tions associated with hepatic congestion/  dysfunction, which 
may potentially decrease argatroban clearance). Coagulation 
parameters should be analyzed carefully.
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